Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03484923 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
A Phase 2 study of Melanoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
- 20
- Study locations
NCT03484923: Completed Phase 2 study of Melanoma, sponsored by Novartis Pharmaceuticals.
NCT03484923 is a Phase 2 study of Melanoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 196 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03484923, a Phase 2 study of Melanoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
Primary Outcome
ORR defined as the percentage of patients with a best overall response of either confirmed complete response (CR) or partial response (PR) as per local review by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and assessed by computed tomography (CT)/ magnetic resonance imaging (MRI). CR:Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm PR: At leas
Conditions Studied
Interventions
- DRUG LEE011
- DRUG PDR001
- DRUG INC280
- DRUG LAG525
- DRUG ACZ885
Study Locations (20)
Other
- Novartis Investigative Site - Marseille
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Villejuif
- Novartis Investigative Site - Dresden
- Novartis Investigative Site - Essen
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Kiel
- Novartis Investigative Site - München
California
- The Angeles Clinic and Research Institute - Los Angeles
- University of California Los Angeles - Los Angeles
- UCSF Medical Center . - San Francisco
New South Wales
- Novartis Investigative Site - North Sydney
- Novartis Investigative Site - Westmead
Massachusetts
- Massachusetts General Hospital Massachusetts Gen. Hospital CC - Boston
New York
- NYU Laura and Isaac Perlmutter Cancer Center Perlmutter Cancer Center - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Ontario
- Novartis Investigative Site - Toronto
Quebec
- Novartis Investigative Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2018-09-10 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 2 |
What the finished NCT03484923 record still lists
NCT03484923 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 5 interventions - of which LEE011 is the first listed.
NCT03484923 names 20 study sites across 10 states, led by Other, California, New South Wales.
Frequently Asked Questions
What is clinical trial NCT03484923 about?
NCT03484923 is a clinical study titled "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma". The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
What is the current status of trial NCT03484923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2018-09-10. Estimated completion is 2022-12-30.
What conditions does trial NCT03484923 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT03484923?
The interventions under investigation include: LEE011 (DRUG), PDR001 (DRUG), INC280 (DRUG), LAG525 (DRUG), ACZ885 (DRUG).
Who is sponsoring clinical trial NCT03484923?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03484923 being conducted?
This trial has 20 study locations across California, Massachusetts, New York, Pennsylvania, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03484923's enrollment target sits among peer trials
196 69th of 266 higher than 198 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI